Vector

Details Vector Vector

2010-02-26

2011-12-27

Angell, J. E. (Department: 1635)

Chemistry: molecular biology and microbiology

Vector, per se

Reexamination Certificate

active

08084249

ABSTRACT:
A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor.

REFERENCES:
patent: 4997913 (1991-03-01), Hallstrom et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5824782 (1998-10-01), Holzer et al.
patent: 5856140 (1999-01-01), Chimamura et al.
patent: 5876691 (1999-03-01), Chester et al.
patent: 6143520 (2000-11-01), Marasco et al.
patent: 6277972 (2001-08-01), Afar et al.
patent: 6348584 (2002-02-01), Hodgson et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6852703 (2005-02-01), Kingsman et al.
patent: 7074909 (2006-07-01), Kingsman et al.
patent: 2007/0161080 (2007-07-01), Kingsman et al.
patent: 0 336 562 (1989-10-01), None
patent: 0803574 (1997-10-01), None
patent: WO-89/07947 (1989-09-01), None
patent: WO-96/30504 (1990-05-01), None
patent: WO-92/11383 (1992-07-01), None
patent: WO-92/22653 (1992-12-01), None
patent: WO-94/11513 (1994-05-01), None
patent: WO-96/15238 (1996-05-01), None
patent: WO-96/30512 (1996-10-01), None
patent: WO-96/34969 (1996-11-01), None
patent: WO-97/17090 (1997-05-01), None
patent: WO-97/36932 (1997-10-01), None
patent: WO-98/55607 (1998-12-01), None
patent: WO-01/36486 (2001-05-01), None
Alvarez et al., “A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients,”Human Gene Therapy,8:229-242 (1997).
Anderson, F.W., “Human gene therapy,” Nature, 392:25-30 (1998).
Arafat et al., “Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv,”Gene Therapy,9:256-262 (2002).
Cameron, E., “Recent Advances in Transgenic Technology,” Mol. Bio., 7:253-265 (1997).
Chamberlain et al., “Costimmulation Enhances the Active Immunotherapy Effect of Recombinant Anticancer Vaccines,” Cancer Research, 56:2832-2836 (1996).
Chaudhary et al., “A rapid method of cloning functional variable-region antibody genes inEscherichia colias single-chain immunotoxins,” PNAS, 87:1066-1070 (1990).
Crystal, R., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,” Science, 270:404-410 (1995).
Deshane et al., “Targeted Tumor Killing via an Intracellular Antibody against erbB-2,”J. Clin. Invest.,96:2980-2989 (1995).
European Search Report for 05 02 5532, dated Jul. 10, 2006.
Forsberg et al., “Identification of Framework Residues in a Secreted Recombinant Antibody Fragment that Control Production Level and Localization inEscherichia coli,” The Jour. of Bio. Chem., 272(19):12430-12436 (1997).
Gerstmayer et al., “Costimulation of T Cell Proliferation by a Chimeric B7-2 Antibody Fusion Protein Specifically Targeted to Cells Expression the erbB2 Proto-Oncogene,”Jour. of Immun.,158:4584-4590 (1997).
Greco et al., “Cancer Gene Therapy: delivery, delivery, delivery,” Frontiers in Bioscience, 7:1516-1524 (2002).
Hammer et al., “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders,” Cell, 63:1099-1112 (1990).
Houdebine, L., “Production of pharmaceutical proteins from transgenic animals,” J. Biotech, 34:269-287 (1994).
Jannot et al., “Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells,”Oncogene,13:275-282 (1996).
Kappel et al., “Regulating gene expression in transgenic animals,” Current Opinions in Biotechnology, 3:548-553 (1992).
Lamikanra et al., “In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies,”Gene Therapy,12:988-998 (2005).
Leong et al., “Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma,” Int. J. Cancer, 71:476-82 (1997).
Mountain, A., “Gene therapy: the first decade,” TIBTECH, 18:119-127 (2000).
Mullins et al., “Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice,” EMBO Journal, 8(13):4065-4072 (1989).
Mullins et al., “Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene,” Nature, 344:541-544 (1990).
Mullins et al., “Transgenesis in Nonmurine Species,” Hypertension, 22:630-633 (1993).
Mullins et al., “Transgenesis in the Rat and Larger Mammals,” J. Clin. Invest., 98:S37-S40 (1996).
Myers et al., “Isolation of a cDNA Encoding 5T4 Oncofetal Trophoblast Glycoprotein,” Jour. of Bio. Chem., 269(12):9319-9324 (1994).
Myers et al., Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins,Cancer Gene Therapy,9:884-896 (2002).
Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science, 272:263-267 (1996).
Niemann, H., “Transgenic farm animals get off the ground,” Transgenic Research, 7:73-75 (1998).
Osaki et al., “Gene Therapy for Carcinoembryonic Antigen-producing Human Lung Cancer Cells by Cell Type-specific Expression of Herpes Simplex Virus Thymidine Kinase Gene,” Cancer Research, 54:5258-5261 (1994).
Overbeek, P., “Factors affecting transgenic animal production,” Transgenic Animal Technology, 96-98 (1994).
Promega, Catalog of Nucleic Acids, pp. 215-216 (1993/94).
Richter et al., “Clinical gene therapy in hematology: Past and future,” Int. Jour. Hematology, 73:162-169 (2001).
Riddell et al., “T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients,” Nature Medicine, 2:216-221 (1996).
Rieger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlag, Berlin (1976).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982).
Scherf et al., “Cytotoxic and Antitumor Activity of a Recombinant Tumor Necrosis Factor-B1(Fv) Fusion Protein on LeYAntigen-expressing Human Cancer Cells,”Clin. Cancer Res.,2:1523-1531 (1996).
Taurog et al., “HLA-B27 in Inbred and Non-Inbred Transgenic Mice,” Jour. of Immun., 141(11):4020-4023 (1988).
Verma et al., “Gene therapy promises, problems and prospects,” Nature, 389:239-242 (1997).
Wall, R.J., “Transgenic Livestock: Progress and Prospects for the Future,” Theriogenology, 45:57-68 (1996).
Walter et al., “Viral Vectors for Gene Transfer,” Drugs, 2:249-271 (2000).
Wels et al., “Biotechnological and gene therapeutic strategies in cancer treatment,”Gene,159:73-80 (1995).
Xiang et al., “Genetic engineering of a recombinant fusion possessing anti-tumor F(ab′)2and tumor necrosis factor,”Jour. of Bio.,53:3-12 (1997).

Affiliated with

Also associated with

Rating

Vector does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vector, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4315502